All News
EULAR 2021 - Day 1 Podcasts
Check out this compilation of our EULAR 2021 Day 1 broadcasts below.
You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com
Listen by Clicking below:
Read Article
Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference
k dao KDAO2011 ( View Tweet)
The case for starting combo Rx for LN (rather than sequential Rx):
👉Aurora trial: voclosporin + MMF (vs. MMF only) prompt efficacy on proteinuria across all ethnic subgroups, twice more complete renal response , no major safety signals. slide 1/ #EULAR2021 @rheumnow https://t.co/TA5i9ITuL7
k dao KDAO2011 ( View Tweet)
OP0131: Pooled data from TULIP-1 and TULIP-2 show anifrolumab (anti-IFN receptor Ab) show improvement of rash and arthritis. Shows promise for drug, particularly in subset of pts with high IFN activity #EULAR2021 @RheumNow https://t.co/sddF2NRlEg
Eric Dein ejdein1 ( View Tweet)
Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 12mo of tx. No worsening C3/C4 & PGA but interestingly #steroid and SLEDAI ⬇️. More works needed to identify suitable pts for taper and regime #EULAR2021 #POS0107 @RheumNow https://t.co/Gwe7mPWPdY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In a UK 🇬🇧 study of newly diagnosed #SLE, Dr Yee reported higher damage in the first 3yrs but then stabilised. Death rate in the first 12yrs had improved to 4.8% (mostly heart disease and infection) but could still occur early (within 5yr diagnosis) #EULAR2021 #POS0111 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In patients with #SLE who attained LLDAS, a retrospective cohort study by Dr Cunha identified predictors of flares including anti-RNP +ve, concomitant immunosuppressant and oral prednisolone. Important to account these during follow-up #EULAR2021 #POS0105 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
🚨So after LoVAS
Now this
Ritux + MMF + Pulse MPS
No oral steroids 🤯
@ARD_BMJ
@EBRheum - Lesser is better ??
https://t.co/CYMNX8wLtd https://t.co/NtwTas3ZdS
EnvisionRheumat ERheumat ( View Tweet)
Promising preclinical data of novel dual BAFF/APRIL inihibitor ALPN-303 re:efficacy & immunomodulatory activity vs TACI-i. Could deplete plasma cell compared to anti-CD20 mAbs in #SLE. Be interesting to see how it’ll fare in future clinical trials #EULAR2021 #OP0039 @RheumNow https://t.co/LnQzO67gwI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE
☑️Older patients
☑️High disease activity
☑️Skin and MSK manifestations
☑️Pts treated before 2000.
Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow
Eric Dein ejdein1 ( View Tweet)
Longitudinal UK SLE inception cohort 273 pts found:
👉⬆️damage in 1st 3 yrs b/f stabilizing at lower rate
👉mortality uncommon in 1st 12 yrs, but can occur w/in 5 yrs of Dx.
👉unexpected⬆️mortality in Caucasians
38% deaths IHD, 23% infx
Abst#0111 #EULAR2021 @rheumnow @Lupusdoc https://t.co/wUwWaB4V2R
k dao KDAO2011 ( View Tweet)
Can you predict flares in SLE pts who achieved LLDAS? Retrospec cohort study from Portugal over 3 years of 292 pts who were in LLDAS, 31% flared. Flares seen more in: 👉pts who require ongoing Rx w/ immmunosuppr, GCs 👉pt w/+RNP Abst#0105 #EULAR2021 @RheumNow https://t.co/xfBqGh4pPP
k dao KDAO2011 ( View Tweet)
C3 and C4⬆️in SLE pregnancy like they would in pregnancies w/o SLE!
French GR2 prospective study of 290 SLE pregnancies quantifies mean C3 value⬆️by 28%, C4⬆️by 11% from 1st ➡️3rd trimester. Remember this when assessing disease activity. #EULAR2021 Abstr #0103 @rheumnow https://t.co/TXjO4mjNJE
k dao KDAO2011 ( View Tweet)
Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and medication safety; it must be favorable, deployable, feasible, and attainable," - Dr. E Morand #EULAR2021 @RheumNow https://t.co/oMMU3AjhmX
k dao KDAO2011 ( View Tweet)
Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk
👉Hormones drive funx change in Treg transciptome
👉anti-inflamm Tregs⬆️in males
👉Tregs are more suppressive in males
👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK
k dao KDAO2011 ( View Tweet)
Plenary abstract #OP0013. In autoimmunity: Male lipoprotein profile: ^ CV risk, but had ^ anti-inflammatory features vs females, 2/2 sex hormones. Possible pathway to dx and tx of inflammatory disease in the future? #EULAR2021 @RheumNow @eular_org https://t.co/Z2KmEQftve
Dr. Rachel Tate uptoTate ( View Tweet)
Prof A Doria introduces SLE-DAS, a new instrument to measure Lupus activity that is continuous and highly sensitive to changes in dz activity #EULAR2021 @rheumnow Watch the oral presentation 6/4/21 Abst#OP0297 https://t.co/gE9QhLL1oj
k dao KDAO2011 ( View Tweet)
What is your treat to target for lupus patients? #EULAR2021 @rheumnow
k dao KDAO2011 ( View Tweet)
"50% of time spent in LLDAS = 50% less damage accrual"- Prof E Morand reviews data on low disease activity state in lupus https://t.co/FU3hPvuyRU
k dao KDAO2011 ( View Tweet)
Prof Van Vollenhoven reveals the Definition of Remission in SLE (DORIS 2021): treating SLE to target #EULAR2021 @rheumnow
👉SLEDAI=0
👉MD global<0.5
👉dsDNA, C3/C4 does not matter
👉prednisone <=5 mg/d, stable meds
👉remission can be met at any point (duration not required https://t.co/TwusJkXR19
k dao KDAO2011 ( View Tweet)
